List of bibliographic references
Number of relevant bibliographic references: 6.
| Ident. | Authors (with country if any) | Title |
|---|
| 000981 (2015) |
Tapan M. Kadia [États-Unis] ; Xavier G. Thomas [France] ; Anna Dmoszynska [Pologne] ; Agnieszka Wierzbowska [Pologne] ; Mark Minden [Canada] ; Christopher Arthur [Australie] ; Jacques Delaunay [France] ; Farhad Ravandi [États-Unis] ; Hagop Kantarjian [États-Unis] | Decitabine Improves Outcomes in Older Patients with Acute Myeloid Leukemia (AML) and Higher Blast Counts |
| 000B10 (2014) |
Martin Weisser [Allemagne] ; Ru-Fang Yeh [États-Unis] ; Guillemette Duchateau-Nguyen [Suisse] ; Giuseppe Palermo [Suisse] ; Tri Quang Nguyen [Suisse] ; Xiaoyan Shi [États-Unis] ; Susanna Y. Stinson [États-Unis] ; Nancy Yu [États-Unis] ; Annika Dufour [Allemagne] ; Tadeusz Robak [Pologne] ; Galina N. Salogub [Russie] ; Anna Dmoszynska [Pologne] ; Philippe Solal-Celigny [France] ; Krzysztof Warzocha [Pologne] ; Javier Loscertales [Espagne] ; John Catalano [Australie] ; Loree Larratt [Canada] ; Viktor A. Rossiev [Russie] ; Isabelle Bence-Bruckler [Canada] ; Christian H. Geisler [Danemark] ; Marco Montillo [Italie] ; Kirsten Fischer [Allemagne] ; Anna-Maria Fink [Allemagne] ; Michael Hallek [Allemagne] ; Johannes Bloehdorn [Allemagne] ; Raymonde Busch [Allemagne] ; Axel Benner [Allemagne] ; Hartmut Döhner [Allemagne] ; Nancy Valente ; Michael K. Wenger [Suisse] ; Stephan Stilgenbauer [Allemagne] ; David Dornan [États-Unis] | PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. |
| 001118 (2012) |
Hagop M. Kantarjian [États-Unis] ; Xavier G. Thomas [France] ; Anna Dmoszynska [Pologne] ; Agnieszka Wierzbowska [Pologne] ; Grzegorz Mazur [Pologne] ; Jiri Mayer [République tchèque] ; Jyh-Pyng Gau [Taïwan] ; Wen-Chien Chou [Taïwan] ; Rena Buckstein [Canada] ; Jaroslav Cermak [République tchèque] ; Ching-Yuan Kuo [Taïwan] ; Albert Oriol [Espagne] ; Farhad Ravandi [États-Unis] ; Stefan Faderl [États-Unis] ; Jacques Delaunay [France, Australie] ; Daniel Lysak [République tchèque] ; Mark Minden ; Christopher Arthur | Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
| 001527 (2010) |
Tadeusz Robak [Pologne, France, Espagne, Australie, Russie, Canada, Danemark, Italie, Nouvelle-Zélande, Hongrie, Suisse, États-Unis] ; Anna Dmoszynska ; Philippe Solal-Celigny ; Krzysztof Warzocha ; Javier Loscertales ; John Catalano ; Boris V. Afanasiev ; Loree Larratt ; Christian H. Geisler ; Marco Montillo ; Ilya Zyuzgin ; Peter S. Ganly ; Caroline Dartigeas ; András Rosta ; Jörg Maurer ; Myriam Mendila ; M. Wayne Saville ; Nancy Valente ; Michael K. Wenger ; Sergey I. Moiseev | Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia |
| 001769 (2008) |
Robert Marcus [Royaume-Uni, Canada, France, Australie, Pologne, Portugal, Belgique, Espagne, Suisse] ; Kevin Imrie ; Philippe Solal-Celigny ; John V. Catalano ; Anna Dmoszynska ; Joao C. Raposo ; Fritz C. Offner ; José Gomez-Codina ; Andrew Belch ; David Cunningham ; Elisabeth Wassner-Fritsch ; George Stein | Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma |
| 001877 (2007) |
Robert Z. Orlowski [États-Unis, Israël, Pays-Bas, Espagne, République tchèque, Australie, Pologne, Canada, Russie, France] ; Arnon Nagler ; Pieter Sonneveld ; Joan Blade ; Roman Hajek ; Andrew Spencer ; Jesus San Miguel ; Tadeusz Robak ; Anna Dmoszynska ; Noemi Horvath ; Ivan Spicka ; Heather J. Sutherland ; Alexander N. Suvorov ; Sen H. Zhuang ; Trilok Parekh ; LIANG XIU ; ZHILONG YUAN ; Wayne Rackoff ; Jean-Luc Harousseau | Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Antineoplastic agent |
| 4 | Cancerology |
| 4 | Comparative study |
| 3 | Phase III trial |
| 2 | Cyclophosphamide |
| 2 | Human |
| 2 | Humans |
| 2 | Immunotherapy |
| 2 | Randomization |
| 2 | Rituximab |
| 2 | Treatment |
| 1 | Acute myelogenous leukemia |
| 1 | Advanced stage |
| 1 | Age |
| 1 | Age Factors |
| 1 | Aged |
| 1 | Antibodies, Monoclonal, Murine-Derived (administration & dosage) |
| 1 | Antimetabolites, Antineoplastic (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 1 | Azacitidine (analogs & derivatives) |
| 1 | Azacitidine (therapeutic use) |
| 1 | B cell neoplasm |
| 1 | Bone Marrow (drug effects) |
| 1 | Bone Marrow (pathology) |
| 1 | Bortezomib |
| 1 | Chemotherapy |
| 1 | Choice |
| 1 | Chronic lymphocytic leukemia |
| 1 | Clinical trial |
| 1 | Combined Modality Therapy |
| 1 | Combined treatment |
| 1 | Cyclophosphamide (administration & dosage) |
| 1 | Cytarabine |
| 1 | Decitabine |
| 1 | Disease-Free Survival |
| 1 | Doxorubicin |
| 1 | Early stage |
| 1 | Elderly |
| 1 | Female |
| 1 | Fludarabine |
| 1 | Focal Adhesion Kinase 1 (genetics) |
| 1 | Follicular lymphoma |
| 1 | Gene Expression |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (enzymology) |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (genetics) |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (therapy) |
| 1 | Leukemia, Myeloid, Acute (drug therapy) |
| 1 | Leukemia, Myeloid, Acute (mortality) |
| 1 | Leukemia, Myeloid, Acute (pathology) |
| 1 | Liposome |
| 1 | Low dose |
| 1 | Lymphoid neoplasm |
| 1 | Male |
| 1 | Middle Aged |
| 1 | Multicenter study |
| 1 | Myeloma |
| 1 | Pegylated form |
| 1 | Physician |
| 1 | Prednisone |
| 1 | Progression free survival |
| 1 | Prolonged |
| 1 | Proportional Hazards Models |
| 1 | RNA, Messenger (genetics) |
| 1 | RNA, Messenger (metabolism) |
| 1 | RNA, Neoplasm (genetics) |
| 1 | RNA, Neoplasm (metabolism) |
| 1 | Recurrence |
| 1 | Relapse |
| 1 | Retrospective Studies |
| 1 | Supportive care |
| 1 | Survival Analysis |
| 1 | Treatment Outcome |
| 1 | Treatment resistance |
| 1 | Vidarabine (administration & dosage) |
| 1 | Vidarabine (analogs & derivatives) |
| 1 | Vincristine |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Anna Dmoszynska"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Anna Dmoszynska" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Anna Dmoszynska
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
